title: Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis.
abstract: The efficacy and safety of uric-acid-lowering therapy (UALT) on slowing the progression of chronic kidney disease (CKD) accompanied by hyperuricemia were assessed. We searched Cochrane Library, PubMed, EMbase, CNKI, Wanfang and Vip databases up to November 15, 2012 for randomized controlled trials (RCTs) which compared the effect of UALT to control therapy in hyperuricemic patients secondary to CKD, and then performed quality evaluation and meta-analysis on the included studies. Seven RCTs involving 451 cases were included. UALT delayed the increase of serum creatinine (MD=-62.55 μmol/L, 95% CI: -98.10 to -26.99) and blood urea nitrogen (MD= -6.15 mmol/L, 95% CI: -8.17 to -4.13) as well as the decrease of glomerular filtration rate [MD=5.65 mL/(min·1.73 m2), 95% CI: 1.88 to 9.41], decreased systolic blood pressure (SBP) (MD= -6.08 mmHg, 95% CI: -11.67 to -0.49), and reduced the risk of the renal disease progression (RR=0.30, 95% CI: 0.19 to 0.46). However, there was no statistically significant difference in 24-h urinary protein quantity and diastolic blood pressure (P>0.05). We identified that UALT could delay the progression of CKD with secondary hyperuricemia. And this also indirectly proved that hyperuricemia was a risk factor for the CKD progression.
authors.affiliation: Department of Nephrology, Huazhong University of Science and Technology, Wuhan, 430030, China.|Department of Ultrasonography, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Ye-Fang
authors.initials: YF
authors.lastname: Zhang
authors.affiliation: Department of Nephrology, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Fan
authors.initials: F
authors.lastname: He
authors.affiliation: Division of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Hong-Hui
authors.initials: HH
authors.lastname: Ding
authors.affiliation: Department of Nephrology, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Dai
authors.affiliation: Department of Nephrology, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Department of Nephrology, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Luan
authors.affiliation: Department of Nephrology, Huazhong University of Science and Technology, Wuhan, 430030, China. lvyongman@126.com.
authors.forename: Yong-Man
authors.initials: YM
authors.lastname: Lv
authors.affiliation: Department of Nephrology, Huazhong University of Science and Technology, Wuhan, 430030, China. mm-885@126.com.
authors.forename: Hong-Bing
authors.initials: HB
authors.lastname: Zeng
mesh_terms: D001794:Blood Pressure; D003404:Creatinine / Q000097:blood; D018450:Disease Progression; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D033461:Hyperuricemia / Q000097:blood* / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D039781:PubMed; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood*
chemical_list: D014527:Uric Acid; D014508:Urea; D003404:Creatinine